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Purpose: Coexistence of different classes of -lactamases in β
a single bacterial isolate may pose diagnostic and therapeutic
challenges. We investigated a spread of Klebsiella pneumoniae
isolates co-producing an AmpC -lactamase and an extended- β
spectrum -lactamase (ESBL) in a university hospital. β Materials
and Methods: Over a three-month period, a total of 11 K.
pneumoniae isolates, which exhibited resistance to cefotaxime,
aztreonam, and cefoxitin, were isolated. These isolates showed
positive to ESBLs by double disk tests. Minimal inhibitory
concentrations (MICs) were determined by broth microdilution
testing. All isolates were examined by isoelectric focusing,
PCR and sequence analysis to identify blaSHV and blaDHA, and
molecular typing by pulsed-field gel electrophoresis (PFGE).
Results: All 11 isolates were highly resistant (MIC, 128 μ
g/ml) to ceftazidime, aztreonam, and cefoxitin, while they
were susceptible (MIC, 2 g/ml) to imipenem. The μ blaSHV-12
and blaDHA-1 genes were detected by PCR and sequence
analysis. PFGE revealed a similar pattern in 10 of the 11
strains tested. Conclusion: This is the first outbreak report of
K. pneumoniae in Korea which co-produced SHV-12 and
DHA-1 -lactamase, and we suggest a clonal spread of β
multidrug-resistant K. pneumoniae at a hospital.
Key Words: Outbreak, Klebsiella pneumoniae, SHV-12,
DHA-1, Extended-spectrum -lactamase, AmpC -lactamase β β
INTRODUCTION
-Lactamase production is the predominant β
mechanism for resistance to -lactams in Entero β -
bacteriaceae. Klebsiella pneumoniae isolates are
often multidrug-resistant and are the major hosts
for extended-spectrum -lactamases (ESBLs). β
1 In
particular, K. pneumoniae strains have also acquired
plasmid-mediated AmpC enzymes. Unlike ESBLs,
AmpCs are poorly inhibited by -lactamase β
inhibitors and are less active against cefepime and
cefpirome than ESBLs. AmpCs confer resistance to
oxyimino- and 7- -methoxy-cephalosporins. α
2 The
prevalence of ESBLs and plasmid-mediated AmpC
-lactamases in β K. pneumoniae has been rising in
Korea. Of the ESBLs and the acquired AmpC
enzymes, SHV-12 and DHA-1 are the most
prevalent and widespread in Korea, respectively.
3,4
Occurrence of ESBL and AmpC -lactamase β
co-producing K. pneumoniae has been reported,
5,6
but outbreaks of the isolates are extremely rare.
Over a three-month period in 2004, K. pneumoniae
isolates resistant to cefotaxime, ceftazidime,
cefepime, aztreonam, and cefoxitin were isolated
from the patients hospitalized at a university
hospital in Korea. The aim of our study was to
analyze clinical and molecular epidemiology of
the multidrug-resistant K. pneumoniae isolates.
MATERIALS AND METHODS
Patients and bacterial isolates
From May to July 2004, a total of 11 non-
duplicated isolates of K. pneumoniae that were
resistant to cefotaxime, ceftazidime, aztreonam,
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and cefoxitin, were identified by Clinical Laboratory
and Standards Institute (CLSI) disk diffusion
method.
7 Ten of the 11 isolates were resistant to
cefepime. All isolates were also resistant to
aminoglycosides (amikacin, gentamicin, and
tobramycin), ciprofloxacin, and trimethoprim-
sulfamethoxazole. All isolates were suggested to
produce ESBL based on the double disk test.
8
Table 1 shows the clinical background of patients
for each isolate and their respective treatment
outcomes. The first isolate from each source of
patient was included in the study.
Susceptibility testing and -lactamase phenotype β
Minimal inhibitory concentrations (MICs) were
determined by the broth microdilution method
according to the CLSI guidelines.
9 The antimicro-
bial agents used were piperacillin (Sigma, Steinheim,
Germany), tazobactam (Yuhan, Seoul, Korea),
cefoxitin (Sigma), ceftazidime (Glaxo SmithKline,
Harlow, UK), aztreonam (Bristol-Myers Squibb,
Prinston, NJ, USA), cefepime (Boryung, Seoul,
Korea), and imipenem (Merk, West Point, PA,
USA). ESBL and AmpC phenotypes were investig-
ated by the CLSI ESBL confirmatory disk diffu-
sion test
7 and the AmpC disk test,
10 respectively.
Isoelectric focusing (IEF)
Crude -lactamase preparations were obtained β
from the isolates by sonication and subjected to
analytical IEF as described previously.
11 - β
Lactamase activity was detected by overlaying the
gels with 0.5 mM nitrocefin in 0.1 M phosphate
buffer, pH 7.0.
PCR amplification and DNA sequencing
Plasmids from the isolates were extracted by a
rapid alkaline lysis procedure.
12 PCR with blaDHA-
13,14 and blaSHV-specific primers and subsequent
sequencing of the PCR products were performed.
An 1,071-bp fragment of the blaSHV gene was
amplified with the primers SHV-F (5’-CGC CGG
GTT ATT CTT ATT TG-3’) and SHV-R (5’-CCA
CGT TTA TGG CGT TAC CT-3’). Sequence align-
ment and analysis were performed on-line using
the BLAST program of the National Center for
Biotechnology Information (www.ncbi.nlm.nih.gov).
Pulsed-field gel electrophoresis (PFGE)
PFGE was carried out with a CHEF-DRII System
(Bio-Rad, Hercules, CA, USA). XbaI-digested
genomic DNA was prepared according to the
instruction of Bio-Rad, and fragments were
separated for 20 h at 6 V/cm at 14 , with initial
and final pulse times of 5 and 40 s, respectively.
DNA bands were visualized by staining the gel
with ethidium bromide and photographed.
RESULTS
Bacterial strains and clinical characteristics
K. pneumoniae isolates were first found to show
resistance to cefotaxime, ceftazidime, cefepime,
aztreonam, and cefoxitin, evidenced by disk dif-
fusion test. During a particular time period, a total
of 11 isolates showing very similar antibiogram
were isolated. These results strongly suggested
that there is coexistence of ESBL and AmpC in
these isolates. The isolates were obtained from 11
inpatients at a hospital; 43 to 87 years old, 9 males
and 2 females, from May to July 2004. Of 11
isolates, 6 isolates were recovered from sputum, 4
isolates from urine, and 1 isolate from a wound.
Isepamicin and cefoperazone-sulbactam had most
frequently been administered in 10 and 9 patients,
respectively. Two of these 11 patients died, and
the infection in the remaining 9 patients improved
with therapy (Table 1).
Antimicrobial susceptibility and -lactamase β
phenotype
These 11 isolates showed very similar suscepti-
bility profiles, characterized by elevated MICs
( 128 g/mL) of piperacillin, piperacillin- μ
tazobactam, cefoxitin, ceftazidime, and aztreonam,
while MICs of imipenem for all of them were
2 g/mL. The MICs of cefepime varied among μ
the strains isolated (Table 2). All the isolates
yielded positive to AmpC disk tests for AmpCs,
double disk tests and CLSI ESBL confirmatory
disk for ESBLs.Co-Producing SHV-12 and DHA-1
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-Lactamase genotype and PFGE profiles β
These isolates had -lactamase bands at isoelectric β
points of 7.6 and 7.8. The blaSHV and blaDHA alleles
were detected by PCR, and the sequences were
identical to those of blaSHV-12 and blaDHA-1. The
PFGE analysis identified one major profile with
four subtypes (Ia, Ib, Ic, and Id) (Table 1, Fig. 1).
Table 1. Clinical and PFGE Data of the Patients with SHV-12 and DHA-1 Co-Producing K. pneumoniae Isolates
Patient
No.
Age/
Sex
Date of Underlying
disease
Previous
medication
Outcome
Isolate 
No.
Source
Floor
(Department)
PFGE
type Admssion Isolation
1
45/M
06/05/04 10/05/04 DM AMK, CRO,
ISP, PTZ
Expired WJ10 Sputum 6th (IM) Ia
2 87/M 13/05/04 10/06/04 Intracranial
hemorrhage
CFS, CFT,
ISP
Improved WJ20 Sputum 3rd (RM) Ib
3 64/M 02/06/04 14/06/04 DM CFS, CLI,
ISP, TEI
Improved WJ23 Sputum 6th (IM) Ia
4 45/M 10/05/04 25/05/04 Cerebral infarct,
COPD, SLE
CFS, ISP Improved WJ28 Urine 3rd (RM) Ia
5 69/F 16/05/04 16/07/04 Cerebral infarct,
myocardial infarct,
Asthma
AMK, CFS,
CLI, FEP,
FLM, ISP,
NET, TEI
Improved WJ30 Sputum MICU (IM) Ia
6 64/M 29/01/04 06/07/04 Aortic dissection AMK, CFS,
CRO, ISP,
MPM, TEI
Expired WJ31 Wound 11th (IM) Ic
7 62/M 10/05/04 25/07/04 Cerebellar cyst CIP, CTX, ISP,
TEI, VAN
Improved WJ32 Urine 8th (NS) Ic
8 46/F 16/04/04 10/05/04 Intracranial
hemorrhage
CFS, CIP,
ISP, NET
Improved WJ34 Urine 3th (RM) II
9 47/M 06/05/04 18/05/04 Chronic renal failure,
COPD, DM
CFS, LEV Improved WJ1 Sputum 11th (IM)  Ia
10 71/M  18/05/04 22/05/04 Pneumothorax,
intracranial
hemorrhage
CFS, ISP,
 IPM
Improved WJ5 Sputum  MICU (IM) Ia
11 43/M 19/04/04 30/05/04 Subdural hematoma,
hemothorax
CFT, ISP,
TEI
Improved WJ7 Urine 8th (NS) Id
MICU, medical intensive care unit; IM, internal medicine; RM, rehabilitation medicine; NS, neurosurgery; DM, diabetes mellitus;
COPD, chronic obstructive pulmonary disease; SLE, systemic lupus erythematosus AMK, amikacin; CFT, cefotiam; CFS,
cefoperazone-sulbactam; CIP, ciprofloxacin; CLI, clindamycin; CRO, ceftriaxone; CTX, cefotaxime; FEP, cefepime; FLM, flomoxef;
IPM, imipenem; ISP, isepamicin; LEV, levofloxacin; MPM, meropenem; NET, netilmicin; PTZ, piperacillin-tazobactam; TEI,
teicoplanin; VAN, vancomycin.
Table 2. MIC Distributions of the 11 SHV-12 and DHA-1 Co-Producing K. pneumoniae Isolates
Antimicrobial agent MIC ( g/mL) distribution (No. of isolates tested) μ
Piperacillin 256 (11)
Piperacillin-tazobactam 256 (11)
Cefoxitin 128 (11)
Ceftazidime 128 (11)
Cefepime 128 (2), 64 (4), 32 (4), 8 (1)
Aztreonam 128 (11)
Imipenem 2 (2), 1 (10)Kyoung Ho Roh, et al.
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DISCUSSION
Expanded-spectrum cephalosporin-resistant orga-
nisms due to ESBL production have been reported
in many countries.
15 ESBL production among K.
pneumoniae isolates in Korea was 28.4% during
2002 - 2003,
16 which is significantly higher than the
United States, Taiwan, or Hong Kong.
1,6 SHV-12,
SHV-2a, and TEM-52 were common in the late
1990s in Korea.
17 In 2002, an SHV-12-like enzyme
was prevalent, but SHV-2a and TEM-52 were
found in a few isolates in Korea.
18 DHA-1, an
inducible plasmid-mediated AmpC that was first
identified in Salmonella enteritidis isolated in Saudi
Arabia in 1992,
19 has been reported in several
other countries.
5,20 DHA-1 enzyme is the most
frequently identified among the AmpC - β
lactamase-producing K. pneumoniae isolates in
Korea.
4 Genes encoding both ESBLs and plasmid-
mediated AmpC -lactamases are usually located β
on large multidrug resistance plasmids. Therefore,
both types of enzymes are typically associated
with resistance to multiple antibiotics, thus
leaving few therapeutic options.
21
In our study, the isolates that co-produced
SHV-12 and DHA-1 enzymes showed high MICs
of ceftazidime, cefepime, aztreonam, and
cefoxitin. Four (8.7%) of 46 plasmid-mediated
AmpC-producing K. pneumoniae isolates also had
an ESBL at a Korean hospital.
14 Furthermore, the
outbreak of K. pneumoniae isolates co-producing
SHV-2a ESBL and DHA-1 AmpC has been
reported in Korea.
22 The nosocomial infections
caused by DHA-1 and SHV-12 -lactamase β
producers occurred in Japan.
23 However, this is
the first report of its occurrence in Korea.
In this study, K. pneumoniae strains were re-
covered from patients with a mean age of 58
years. These data agree with a previous study
showing usually older with ESBL.
24 However, the
mean age (55 years old) of the other 164 patients
who were infected with broad-spectrum cephalo-
sporins-susceptible K. pneumoniae was older in age
(data not shown). The extended-spectrum cephalo-
sporins had preferentially been used as first-line
drugs at the hospital. Among 11 patients, all of
them had received the extended-spectrum
cephalosporins (9 had received cefoperazone-
sulbactam). The emergence of multi-resistant
organisms, characterized by a heavy use of anti-
microbial agents, may provide nosocomial
transmission.
25 In our present study, the
emergence of K. pneumoniae isolates co-producing
SHV-12 and DHA-1 could be correlated with
heavy use of extended-spectrum cephalosporins.
PFGE of XbaI-digested genomic DNA revealed
that 10 out of the 11 isolates in this study, likely
corresponded to a single clone, whereas one
isolate (WJ34) was not clonally related.
In conclusion, the first outbreak caused by K.
pneumoniae isolates co-producing SHV-12 ESBL
and DHA-1 AmpC -lactamase occurred at a β
university hospital in Korea. The spreads was
caused by an endemic clone of the resistance gene.
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Fig. 1. PFGE dendrograms of 11 SHV-12 and
DHA-1 co-producing K. pneumoniae isolates. The
scale indicates the percent of genetic similarity.
The molecular size marker includes yeast
chromosomes, Saccharomyces cerevisiae (Bio-Rad
Laboratories, Hercules, CA, USA).Co-Producing SHV-12 and DHA-1
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